Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study).

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-04-09 DOI:10.1186/s13550-025-01232-8

Salma Binzaqr, David Kryza, Anne-Laure Giraudet, Jean Christophe Bernhard, Marine Gross-Goupil, Mokrane Yacoub, Gaelle Margue, Elif Hindié, Clément Morgat

{"title":"Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study).","authors":"Salma Binzaqr, David Kryza, Anne-Laure Giraudet, Jean Christophe Bernhard, Marine Gross-Goupil, Mokrane Yacoub, Gaelle Margue, Elif Hindié, Clément Morgat","doi":"10.1186/s13550-025-01232-8","DOIUrl":null,"url":null,"abstract":"Background: Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and RCC metastases according to metastatic sites are rare. 44 frozen samples of RCC, 19 primaries (9 clear cell (cc) RCC, 7 papillary (pap) RCC, and 3 chromophobe (ch) RCC) and 25 (24 samples have ccRCC histology and one is unclassified) unpaired metastases (8 from adrenals, 8 from bones, 2 from lungs, 2 from liver and 5 others (1 lymph node, 1 pancreas, 1 brain, 1 gallbladder and 1 muscle)), were available from the UroCCR project (NCT03293563). PSMA expression was assessed by autoradiography using [177Lu]Lu-PSMA-617 as binding agent and the specific binding (total binding-non-specific binding) was calculated and expressed as a percentage of total binding. A patient suffering from metastatic ccRCC was also administered [68Ga]Ga-PSMA-11 to evaluate PSMA expression.Results: The mean specific binding was 28.9 ± 40.4% for primary renal cancer and 65.0 ± 38.9% for metastasis. Regarding histology, high PSMA expression was depicted in 33.3% of ccRCC, 33.3% of chRCC and 57.1% of papRCC. PSMA was more frequently expressed in primary samples of papRCC histology with renal capsule invasion (p = 0.0286). A higher PSMA-specific binding and a higher number of samples with high PSMA-expression were depicted in metastatic samples. Bone metastasis showed lower binding than other metastatic sites combined (p = 0.0005). The patient suffering from metastatic ccRCC showed high [68Ga]Ga-PSMA-11 uptake on known distant metastases and additional site uncovered.Conclusion: PSMA showed high expression in metastases of ccRCC.Clinical trial registration: NCT, NCT03293563, prospectively registered September 20, 2017, http://www.Clinicaltrials: gov .","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"38"},"PeriodicalIF":3.1000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981970/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01232-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and RCC metastases according to metastatic sites are rare. 44 frozen samples of RCC, 19 primaries (9 clear cell (cc) RCC, 7 papillary (pap) RCC, and 3 chromophobe (ch) RCC) and 25 (24 samples have ccRCC histology and one is unclassified) unpaired metastases (8 from adrenals, 8 from bones, 2 from lungs, 2 from liver and 5 others (1 lymph node, 1 pancreas, 1 brain, 1 gallbladder and 1 muscle)), were available from the UroCCR project (NCT03293563). PSMA expression was assessed by autoradiography using [¹⁷⁷Lu]Lu-PSMA-617 as binding agent and the specific binding (total binding-non-specific binding) was calculated and expressed as a percentage of total binding. A patient suffering from metastatic ccRCC was also administered [⁶⁸Ga]Ga-PSMA-11 to evaluate PSMA expression.

Results: The mean specific binding was 28.9 ± 40.4% for primary renal cancer and 65.0 ± 38.9% for metastasis. Regarding histology, high PSMA expression was depicted in 33.3% of ccRCC, 33.3% of chRCC and 57.1% of papRCC. PSMA was more frequently expressed in primary samples of papRCC histology with renal capsule invasion (p = 0.0286). A higher PSMA-specific binding and a higher number of samples with high PSMA-expression were depicted in metastatic samples. Bone metastasis showed lower binding than other metastatic sites combined (p = 0.0005). The patient suffering from metastatic ccRCC showed high [⁶⁸Ga]Ga-PSMA-11 uptake on known distant metastases and additional site uncovered.

Conclusion: PSMA showed high expression in metastases of ccRCC.

Clinical trial registration: NCT, NCT03293563, prospectively registered September 20, 2017, http://www.

Clinicaltrials: gov .

查看原文本刊更多论文

前列腺特异性膜抗原（PSMA）在原发性和转移性肾细胞癌中的表达（UroCCR-65研究）。

背景：前列腺特异性膜抗原（PSMA）已被证实在肾癌的新生血管中过度表达。然而，根据转移部位调查原发性RCC和转移性RCC中PSMA表达模式的研究很少。从UroCCR项目（NCT03293563）中获得了44例RCC冷冻样本，19例原发（9例透明细胞RCC， 7例乳头状RCC， 3例避色细胞RCC）和25例（24例具有ccRCC组织学，1例未分类）未配对转移(8例来自肾上腺，8例来自骨骼，2例来自肺部，2例来自肝脏和其他5例（1例淋巴结，1例胰腺，1例脑，1例胆囊和1例肌肉）。使用[177Lu]Lu-PSMA-617作为结合剂，通过放射自显影评估PSMA表达，计算特异性结合（总结合-非特异性结合），并以总结合的百分比表示。一名患有转移性ccRCC的患者也接受了[68Ga]Ga-PSMA-11来评估PSMA的表达。结果：原发性肾癌的特异性结合率为28.9±40.4%，转移性肾癌的特异性结合率为65.0±38.9%。在组织学上，33.3%的ccRCC、33.3%的chRCC和57.1%的papRCC中存在PSMA高表达。PSMA在肾包膜浸润的原发性肾癌组织中表达频率更高（p = 0.0286）。更高的psma特异性结合和更高数量的psma高表达样本在转移样本中被描述。骨转移的结合低于其他转移部位的结合（p = 0.0005）。患有转移性ccRCC的患者在已知的远处转移和未发现的其他部位显示出高[68Ga]Ga-PSMA-11摄取。结论：PSMA在ccRCC转移灶中有高表达。临床试验注册：NCT， NCT03293563，预期注册于2017年9月20日，http://www.Clinicaltrials: gov。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.